Prediction of Left Ventricular Adverse Remodeling and Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction Though Plasma Multiomics Analysis.
Launched by BEIJING ANZHEN HOSPITAL · Mar 14, 2025
Trial Information
Current as of April 23, 2025
Active, not recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years.
- • 2. Diagnosis of AMI (STEMI or NSTEMI) confirmed by clinical criteria, electrocardiogram (ECG), and cardiac biomarkers (e.g., troponin).
- • 3. Willingness to provide informed consent.
- Exclusion Criteria:
- • 1. Prior surgery or trauma.
- • 2. Renal failure with glomerular filtration \<30 ml/min.
Trial Officials
Xu Wang, Dr.
Principal Investigator
Beijing Anzhen hospital, Capital Mediacl University.
Tanxi Cai, Dr.
Study Director
Institute of Biophysics, Chinese Academy of Sciences
About Beijing Anzhen Hospital
Beijing Anzhen Hospital is a leading medical institution in China, renowned for its expertise in cardiovascular diseases and comprehensive healthcare services. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and innovation, facilitating the development of new therapies and treatment protocols. With a focus on patient safety and ethical standards, Beijing Anzhen Hospital collaborates with various research entities to conduct rigorous clinical studies aimed at improving patient outcomes and enhancing the understanding of cardiovascular health. Its commitment to excellence in clinical research is underscored by a multidisciplinary team of experienced healthcare professionals and a state-of-the-art facility equipped to support a wide range of clinical investigations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
